CN Patent

CN111278466A — 伊马替尼的液体剂型

Assigned to Ft Pharma Pte Ltd · Expires 2020-06-12 · 6y expired

What this patent protects

伊马替尼被批准并以固体口服剂型市售，所述固体口服剂型可分散于水或苹果汁中以用于吞咽困难的患者。伊马替尼固体剂型在苹果汁中的分散体可增加适口性和患者依从性，但苹果汁可能并非始终可用于施用。此外，伊马替尼固体口服剂型的分散体可能不会每次施用正确且一致的药物剂量。因此，本发明提供了正确且一致地向所述患者施用正确药物剂量的伊马替尼液体剂型。

USPTO Abstract

伊马替尼被批准并以固体口服剂型市售，所述固体口服剂型可分散于水或苹果汁中以用于吞咽困难的患者。伊马替尼固体剂型在苹果汁中的分散体可增加适口性和患者依从性，但苹果汁可能并非始终可用于施用。此外，伊马替尼固体口服剂型的分散体可能不会每次施用正确且一致的药物剂量。因此，本发明提供了正确且一致地向所述患者施用正确药物剂量的伊马替尼液体剂型。

Drugs covered by this patent

Patent Metadata

Patent number
CN111278466A
Jurisdiction
CN
Classification
—
Expires
2020-06-12
Drug substance claim
No
Drug product claim
No
Assignee
Ft Pharma Pte Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.